VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IWWM-11 2022 | FDA approval of teclistamab for R/R multiple myeloma and the value of immunotherapies

Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, briefly highlights the recent FDA approval of teclistamab for relapsed/refractory (R/R) multiple myeloma, and the growing value of immunotherapies in this space. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter